Follicular lymphoma (FL) is a rare, slow-growing cancer that affects certain blood cells. People experiencing this form of non-Hodgkin lymphoma face multiple relapses over the course of their disease, which can run for years and sometimes decades. There is no cure. For a small number of patients, the disease progresses much faster, and they face five-year survival rates as low as 50 percent.

MI Philanthropy, in partnership with the Follicular Lymphoma Foundation (FLF), conducted an in-depth analysis of the FL landscape. This report identifies current and emerging therapeutic innovations in the FL field, and highlights efforts of the FLF to drive research into better treatments and find the fastest pathway to a cure. Importantly, this analysis demonstrates that although drug development for FL has been burgeoning in the past five years, there are key areas that should be addressed to accelerate the path to a cure.